Covid Drug: New oral antiviral drug likely to get Centre’s approval for treating Covid, Health News, ET HealthWorld

Pune: The Union health ministry is likely to include an oral antiviral drug, nirmatrelvir-ritonavir combination, in the country’s upcoming Covid treatment protocol for patients with mild to moderate disease, who are at high risk of developing severe illness. The combination drug, popularly known by the brand name paxlovid, is currently in high demand in China and a few other nations battling the Covid surge. India’s upcoming Covid treatment protocol is expected to be released within a week. “The combination two-tablet oral drug therapy is likely to be recommended in India…

Read More

Covid resurgence brings back Remdesivir, Tosi in demand – ET HealthWorld

Nagpur: Covid cases have almost touched the 300-mark in the fourth wave. With increase in number of hospitalizations and some patients turning critical, the demand for drugs like Remdesivir and Tocilizumab too has increased. The two drugs were in high demand during the second wave last year, but after Covid cases dipped, there had been almost no takers for them. Infectious diseases specialist Dr Nitin Shinde said Remdesivir was prescribed to some outdoor patient department (OPD) patients in the fourth wave. “I had also administered Tocilizumab. Some patients were also…

Read More

Govt Issues Guidelines On Use Of Remdesivir, Tocilizumab

There is no evidence of injectable steroids benefitting Covid patients not requiring oxygen supplementation or in continuation after discharge, according to the revised ‘Clinical Guidance for Management of Adult COVID-19 Patients’. The revised guidelines issued by AIIMS, ICMR-COVID-19 National Task Force and Joint Monitoring Group (DGHS) under the Union health ministry also stated that anti-inflammatory or immunomodulatory therapy, such as steroids, can have the risk of secondary infection like invasive mucormycosis, when used too early, at higher dose or for longer than required. Injection methylprednisolone 0.5 to one mg/kg in…

Read More

Remdesivir to be used in patients with moderate to severe COVID-19: Health ministry – ET HealthWorld

The Centre on Friday said Remdesivir drug should only be used in patients with ‘moderate to severe’ COVID-19 and those with no renal or hepatic dysfunction within 10 days of the onset of any symptom. It also warned against use of the drug in patients who are not on oxygen support or in home settings. According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be “used in patients with moderate to severe COVID-19 and those…

Read More

2 in 5 Indians who got Covid treatment in hospitals during second wave had to pay a bribe – ET HealthWorld

NEW DELHI: Two in five Indians who were treated for Covid-19 during the second wave has to pay a bribe, reveals a survey by Local Circles. The survey received over 16,000 responses from citizens spread across 317 districts of India. Of those who had to pay a bribe at a hospital, 82% paid it to get admission, bed, ventilator or medicines; 9% paid it to reduce the bill amount or timely insurance processing; and 9% to get information or visit someone in ICU. No one paid a bribe to doctors…

Read More

India’s role as pharmacy of world becomes more entrenched as nation inoculates over 100 cr COVID-19 vaccine doses – ET HealthWorld

New Delhi: As the country achieved the milestone of vaccinating over 100 crore Indians against COVID-19 on Thursday, India’s role as the pharmacy of the world became more entrenched with the nation manufacturing COVID vaccines and many drugs used in the treatment against the virus. Even after witnessing the havoc created by the two waves of the pandemic, India emerged out of its effects by ramping up the pharma manufacturing sector and maintaining a resilient supply chain of essential drugs. The Centre in an official statement has stated that vaccination…

Read More

Union Health Minister reviews availability of COVID-19 essential drugs, their buffer stocks – ET HealthWorld

During the review, it was noted that sufficient stocks of all the essential medicines are available. Raw materials for these drugs are also available in enough quantities, according to the Ministry of Health and Family Welfare ANI September 02, 2021, 18:07 IST Source link

Read More

Centre stockpiling critical drugs to fight another possible Covid wave – ET HealthWorld

Mumbai: The government has kick-started an exercise to create a national stockpile of critical medicines for Covid-19 to tide over the challenges around affordability and accessibility as it prepares for a possible third wave. To begin with, buffer stocks of 15-odd medicines, including anti-viral Remdesivir, key antibiotics Tocilizumab, and black fungus drug Amphotericin B will be maintained, after supplies are procured through the tendering process, sources told TOI . This could prevent the massive shortages of critical drugs like Remdesivir, Tocilizumab, key antibiotics and ICU medication, witnessed during the brutal…

Read More

Scientists find new drug target to treat coronavirus, fight future pandemic – ET HealthWorld

Scientists have identified a novel target for a drug that can treat the SARS-CoV-2 virus, which causes COVID-19, and also help tackle a future coronavirus pandemic. The researchers at Northwestern University Feinberg School of Medicine in the US noted that scientists should prepare for a possible next coronavirus pandemic. “God forbid we need this, but we will be ready,” said Karla Satchell, professor of microbiology-immunology at Feinberg School of Medicine. The team previously mapped the structure of a virus protein called nsp16, which is present in all coronaviruses. The latest…

Read More

Remdesivir, tocilizumab helped patients: Study – ET HealthWorld

Mumbai: Severely ill Covid-19 patients fared better when they received remdesivir and tocilizumab, two experimental drugs given individually or in combination, than those who did not get them, observed doctors from KEM Hospital, a premier medical college and hospital. The survival rate in patients receiving either or both the drugs was 64%; it dropped to 34% among those who did not get any of the two. In the group that benefitted, the rate of discharge among those given only remdesivir was 66%, for those who got only tocilizumab it was…

Read More